Back to top

HOPE Logo

 

 

 

 

 

 

HIV Open Label Prevention Extension – An open-label follow-on trial to ASPIRE (MTN-020) in which former ASPIRE participants were offered the opportunity to use the dapivirine ring (there was no placebo) in the context of a study designed to collect additional information about safety and how women would use the ring knowing that it was shown to reduce the risk of HIV in ASPIRE. HOPE enrolled 1,456 women at 14 sites in Malawi, South Africa, Uganda and Zimbabwe. Women were free to accept the ring or not, and to change their minds at any time during the study. Results, which were presented at IAS 2019, found that ring was well-tolerated, consistent with the safety profile seen in ASPIRE, and the majority of women from ASPIRE chose the ring being offered.  Measures of adherence also indicated they were willing to use the ring to protect themselves against HIV.

 

Results of open-label study of a vaginal ring for HIV prevention suggest women are interested in and willing to use it

23-July-2019

 

Women’s use of vaginal ring is higher in open-label study, as is level of HIV protection

6-March-2018

  

HOPE Q&A

23-July-2019

  

See Also

MTN-025 Protocol

 

MTN-025 Study Page

 

Next steps and planned studies of the dapivirine vaginal ring

11-October-2017

     

HOPE open-label study of vaginal ring for preventing HIV begins for former ASPIRE participants

18-July-2016 

  

ASPIRE (MTN-020)